664 Thrombospondin 1 is a major activator of TGF-beta in Recessive Dystrophic Epidermolysis Bullosa

V.S. Atanasova, R. Russell, T.G. Webster, J Salas, A. South

Research output: Contribution to journalMeeting Abstract

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disease caused by loss of function mutations in the gene encoding type VII collagen (COL7A1). RDEB is characterized by trauma induced wounds and excessive scarring, and one of the most frequent complications in RDEB is the development of fatal squamous cell carcinoma (SCC). Our published and unpublished data show that TGF-beta signaling is increased in RDEB, and others have shown that TGF-beta is a major disease modifier. We previously demonstrated that the matricellular protein thrombospondin-1 (TSP1) is increased in RDEB fibroblasts and that COL7A1 expression modulates TSP1. Here we investigated the role of TSP1 in TGF-beta activation in RDEB primary fibroblasts. Knock-down of TSP1 reduced phosphorylation of SMAD3 (a downstream target of TGF-beta signaling) in RDEB patient fibroblasts, but not in non-RDEB normal breast fibroblasts. Over-expression of COL7A1 in RDEB fibroblasts reduced intracellular TSP1 and phosphorylated SMAD3. Furthermore, peptide inhibition of TSP1 binding to the TGF-beta – latency associated protein complex decreased nuclear localization of phosphorylated SMAD3 in tissue engineered extracellular matrix (ECM) from RDEB fibroblasts compared with controls and to a similar extent as observed after SB-431542 inhibition of the TGF-beta type I receptor. Decreased nuclear phosphorylated SMAD3 correlated with a decrease in collagen fiber formation in tissue engineered ECM from RDEB fibroblasts treated with the peptide TSP1 inhibitor, as evaluated by picrosirius red staining followed by analyses of birefringent collagen fibrillar deposits using a polarizing microscope. These data suggest TSP1 is a major activator of TGF-beta signaling in RDEB and identify TSP1 as a potent therapeutic target.

Original languageEnglish
Pages (from-to)S307
JournalJournal of Investigative Dermatology
Volume137
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017

Fingerprint

Epidermolysis Bullosa Dystrophica
Thrombospondin 1
Transforming Growth Factor beta
Fibroblasts
Collagen Type VII
Fibrillar Collagens
Tissue
Extracellular Matrix
Genetic Skin Diseases
Peptides
Phosphorylation
Gene encoding
Skin
Wounds and Injuries
Proteins
Microscopes
Collagen
Deposits
Chemical activation
Cicatrix

Cite this

Atanasova, V.S. ; Russell, R. ; Webster, T.G. ; Salas, J ; South, A. / 664 Thrombospondin 1 is a major activator of TGF-beta in Recessive Dystrophic Epidermolysis Bullosa. In: Journal of Investigative Dermatology. 2017 ; Vol. 137, No. 10. pp. S307.
@article{d903ad03d5d64e17bdadafe0f37ef4d8,
title = "664 Thrombospondin 1 is a major activator of TGF-beta in Recessive Dystrophic Epidermolysis Bullosa",
abstract = "Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disease caused by loss of function mutations in the gene encoding type VII collagen (COL7A1). RDEB is characterized by trauma induced wounds and excessive scarring, and one of the most frequent complications in RDEB is the development of fatal squamous cell carcinoma (SCC). Our published and unpublished data show that TGF-beta signaling is increased in RDEB, and others have shown that TGF-beta is a major disease modifier. We previously demonstrated that the matricellular protein thrombospondin-1 (TSP1) is increased in RDEB fibroblasts and that COL7A1 expression modulates TSP1. Here we investigated the role of TSP1 in TGF-beta activation in RDEB primary fibroblasts. Knock-down of TSP1 reduced phosphorylation of SMAD3 (a downstream target of TGF-beta signaling) in RDEB patient fibroblasts, but not in non-RDEB normal breast fibroblasts. Over-expression of COL7A1 in RDEB fibroblasts reduced intracellular TSP1 and phosphorylated SMAD3. Furthermore, peptide inhibition of TSP1 binding to the TGF-beta – latency associated protein complex decreased nuclear localization of phosphorylated SMAD3 in tissue engineered extracellular matrix (ECM) from RDEB fibroblasts compared with controls and to a similar extent as observed after SB-431542 inhibition of the TGF-beta type I receptor. Decreased nuclear phosphorylated SMAD3 correlated with a decrease in collagen fiber formation in tissue engineered ECM from RDEB fibroblasts treated with the peptide TSP1 inhibitor, as evaluated by picrosirius red staining followed by analyses of birefringent collagen fibrillar deposits using a polarizing microscope. These data suggest TSP1 is a major activator of TGF-beta signaling in RDEB and identify TSP1 as a potent therapeutic target.",
author = "V.S. Atanasova and R. Russell and T.G. Webster and J Salas and A. South",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.jid.2017.07.341",
language = "English",
volume = "137",
pages = "S307",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "10",

}

664 Thrombospondin 1 is a major activator of TGF-beta in Recessive Dystrophic Epidermolysis Bullosa. / Atanasova, V.S.; Russell, R.; Webster, T.G.; Salas, J; South, A.

In: Journal of Investigative Dermatology, Vol. 137, No. 10, 01.10.2017, p. S307.

Research output: Contribution to journalMeeting Abstract

TY - JOUR

T1 - 664 Thrombospondin 1 is a major activator of TGF-beta in Recessive Dystrophic Epidermolysis Bullosa

AU - Atanasova, V.S.

AU - Russell, R.

AU - Webster, T.G.

AU - Salas, J

AU - South, A.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disease caused by loss of function mutations in the gene encoding type VII collagen (COL7A1). RDEB is characterized by trauma induced wounds and excessive scarring, and one of the most frequent complications in RDEB is the development of fatal squamous cell carcinoma (SCC). Our published and unpublished data show that TGF-beta signaling is increased in RDEB, and others have shown that TGF-beta is a major disease modifier. We previously demonstrated that the matricellular protein thrombospondin-1 (TSP1) is increased in RDEB fibroblasts and that COL7A1 expression modulates TSP1. Here we investigated the role of TSP1 in TGF-beta activation in RDEB primary fibroblasts. Knock-down of TSP1 reduced phosphorylation of SMAD3 (a downstream target of TGF-beta signaling) in RDEB patient fibroblasts, but not in non-RDEB normal breast fibroblasts. Over-expression of COL7A1 in RDEB fibroblasts reduced intracellular TSP1 and phosphorylated SMAD3. Furthermore, peptide inhibition of TSP1 binding to the TGF-beta – latency associated protein complex decreased nuclear localization of phosphorylated SMAD3 in tissue engineered extracellular matrix (ECM) from RDEB fibroblasts compared with controls and to a similar extent as observed after SB-431542 inhibition of the TGF-beta type I receptor. Decreased nuclear phosphorylated SMAD3 correlated with a decrease in collagen fiber formation in tissue engineered ECM from RDEB fibroblasts treated with the peptide TSP1 inhibitor, as evaluated by picrosirius red staining followed by analyses of birefringent collagen fibrillar deposits using a polarizing microscope. These data suggest TSP1 is a major activator of TGF-beta signaling in RDEB and identify TSP1 as a potent therapeutic target.

AB - Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disease caused by loss of function mutations in the gene encoding type VII collagen (COL7A1). RDEB is characterized by trauma induced wounds and excessive scarring, and one of the most frequent complications in RDEB is the development of fatal squamous cell carcinoma (SCC). Our published and unpublished data show that TGF-beta signaling is increased in RDEB, and others have shown that TGF-beta is a major disease modifier. We previously demonstrated that the matricellular protein thrombospondin-1 (TSP1) is increased in RDEB fibroblasts and that COL7A1 expression modulates TSP1. Here we investigated the role of TSP1 in TGF-beta activation in RDEB primary fibroblasts. Knock-down of TSP1 reduced phosphorylation of SMAD3 (a downstream target of TGF-beta signaling) in RDEB patient fibroblasts, but not in non-RDEB normal breast fibroblasts. Over-expression of COL7A1 in RDEB fibroblasts reduced intracellular TSP1 and phosphorylated SMAD3. Furthermore, peptide inhibition of TSP1 binding to the TGF-beta – latency associated protein complex decreased nuclear localization of phosphorylated SMAD3 in tissue engineered extracellular matrix (ECM) from RDEB fibroblasts compared with controls and to a similar extent as observed after SB-431542 inhibition of the TGF-beta type I receptor. Decreased nuclear phosphorylated SMAD3 correlated with a decrease in collagen fiber formation in tissue engineered ECM from RDEB fibroblasts treated with the peptide TSP1 inhibitor, as evaluated by picrosirius red staining followed by analyses of birefringent collagen fibrillar deposits using a polarizing microscope. These data suggest TSP1 is a major activator of TGF-beta signaling in RDEB and identify TSP1 as a potent therapeutic target.

U2 - 10.1016/j.jid.2017.07.341

DO - 10.1016/j.jid.2017.07.341

M3 - Meeting Abstract

VL - 137

SP - S307

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 10

ER -